This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q91.1 | Special Copayment Reduction: V160 | Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Adult survival possible (few) — The mosaic form has a higher survival rate than the complete form, and when the proportion of abnormal cells is low, cases surviving to adolescence or adulthood are rarely reported. Phenotypic heterogeneity is large, and there are also mild mosaic cases first diagnosed in adulthood. |
| 1. History | Mosaic cases accumulated after the description of the complete form (1960). Recognition of clinical diversity according to the cell mixture ratio. |
| 2. Causes | Mixture of 46/47 cells due to nondisjunction in early cleavage (mitosis) of the zygote. |
| 3. Genetics | mos 47,+18[n]/46[n]. The proportion of abnormal cells determines phenotypic severity. Low recurrence risk. |
| 4. General epidemiology | About 2–5% of all trisomy 18. Occurrence is sporadic. Low dependence on maternal age. |
| 5. Pathophysiology | Mitotic nondisjunction in the early embryo → coexistence of normal/trisomic cells. The ratio varies under cellular selection pressure. |
| 6. Symptoms | Phenotype may be milder than the complete form. Wide clinical spectrum according to the proportion and distribution of abnormal cells. |
| 7. Signs | Overlaps with signs of the complete form but varies from mild to severe. Difficult to distinguish from the complete form by physical examination alone. |
| 8. Screening | Sensitivity of NIPT and serum screening may be reduced. Invasive testing if ultrasound is abnormal. Karyotype if clinically suspected after birth. |
| 9. Diagnosis | Standard karyotype analysis (counting many cells), multi-site tissue FISH, SNP array. Beware of possible false negatives. |
| 10. Treatment | No fundamental treatment. Similar to the complete form, but because survival is higher, the proportion of active supportive treatment increases. |
| 11. Prognosis | Survival higher than the complete form. 1-year survival rate about 30–40% (some reports). The proportion of abnormal cells is key to prognosis. |
| 12. Prevention | No specific prevention for the mosaic form. Same approach as the complete form in prenatal diagnosis. Genetic counseling needed. |
| 13. References | Edwards JH (1960) and 9 others. |
The history of the trisomy 18 mosaic form (mosaic trisomy 18) begins after the complete form of Edwards syndrome was first described in 1960, as karyotype analysis became routine and cell populations in which normal cells (46 chromosomes) and trisomic cells (47 chromosomes, 3 copies of chromosome 18) coexist were identified in some patients. From the early 1960s, several investigators reported that cellular mosaicism can attenuate the clinical phenotype of Edwards syndrome, and in particular a correlation was suggested in which a higher proportion of normal cells means longer survival and lower severity of malformations.
From the 1970s, standardization of G-banding karyotype analysis made systematic classification and reporting of mosaic cases possible. During this period it became clear that the mosaic form is mechanistically distinct from the complete form (meiotic nondisjunction, Q91.0). The mosaic form arises from mitotic nondisjunction during early cleavage after fertilization, whereas the complete form arises from meiotic nondisjunction at the stage of gamete formation.
The clinical importance of the mosaic form lies in its phenotypic heterogeneity. Even within the same mosaic form, depending on the proportion of abnormal cells and the tissues and organs in which abnormal cells are distributed, there is a wide clinical spectrum from a nearly normal phenotype to severe malformations similar to the complete form. As a result, some patients with the mosaic form survive to adulthood, and cases first diagnosed in adulthood are even rarely reported. This is a scenario that is almost impossible in complete Edwards syndrome.
Since the 2000s, as molecular genetic techniques based on FISH, microarray, and NGS became widespread, the diagnostic sensitivity for the mosaic form has improved greatly. However, what must be noted in diagnosing the mosaic form is that when the proportion of abnormal cells is low (<10%), it can be missed on standard karyotype analysis. Recognizing this possibility of false negatives, when Edwards syndrome is strongly suspected clinically but the standard karyotype is normal, it is recommended to analyze many cells or additionally test other tissues (skin fibroblasts, etc.).
In Korea as well, cases of the Edwards syndrome mosaic form are rarely reported, and together with the complete form it is included in the rare disease Special Copayment Reduction V160. Because of the small number of cases, research on aggressive treatment and long-term prognosis of the mosaic form relies mainly on case reports and small cohort studies.
The trisomy 18 mosaic form (Q91.1) arises from mitotic nondisjunction occurring during cleavage in early embryonic development after formation of the zygote. This is the fundamental difference in mechanism from the complete form (Q91.0, meiotic nondisjunction).
Mitotic nondisjunction occurs when the sister chromatids of chromosome 18 fail to separate normally during somatic cell division and move to the same daughter cell. As a result, one daughter cell has 3 chromosomes 18 (trisomic cell, 47,+18) and the other daughter cell has 1 chromosome 18 (monosomic cell, 45,−18). Monosomic cells are disadvantaged for survival and are mostly lost, and a state is maintained in which trisomic cells and normal cells (46, already normally divided cells) coexist.
The proportion of abnormal cells is determined by the point in embryonic development at which nondisjunction occurs. The earlier nondisjunction occurs (2-cell stage, 4-cell stage), the higher the proportion of abnormal cells; the later it occurs (after the blastocyst), the lower the proportion. Therefore, the proportion of abnormal cells in the mosaic form differs between individuals, and this proportion is related to the severity of the clinical phenotype.
Some mosaic forms arise starting from a complete trisomic zygote (trisomy 18 zygote), when a normal cell lineage is generated in some cells by correction by nondisjunction or trisomy rescue. In this case, uniparental disomy (UPD) can occur in the normal-appearing cells, so it may be clinically important to determine whether UPD 18 is present.
Unlike the complete form, the occurrence of the mosaic form has a low correlation with maternal age. Because it arises from random errors in embryonic development after fertilization, the advanced maternal age risk factor does not apply as strongly as it does to the complete form. Therefore, the mosaic form can occur in young mothers as well.
The karyotype of the trisomy 18 mosaic form is written as mos 47,XX,+18[n]/46,XX[m] or mos 47,XY,+18[n]/46,XY[m], where the numbers n and m in brackets indicate the numbers of analyzed trisomic cells and normal cells, respectively. The proportion of abnormal cells (n/n+m × 100%) is clinically important information.
The proportion of abnormal cells may differ by tissue. The proportion measured in peripheral blood lymphocytes does not necessarily represent the proportion in other tissues (skin fibroblasts, brain, heart). The proportion of abnormal cells may be higher in organs with more severe clinical malformations (e.g., heart, brain). This is called tissue-specific mosaicism or confined mosaicism. Conversely, even if the proportion of abnormal cells in peripheral blood is high, the proportion in key organs may be low, resulting in a mild phenotype. This tissue heterogeneity is the main reason it is difficult to predict the phenotype of the mosaic form.
Regarding recurrence risk, the mosaic form also occurs sporadically with normal parental karyotypes, so the recurrence risk is low. However, because germline mosaicism is theoretically possible, prenatal genetic diagnosis is recommended in the next pregnancy. Some studies suggest that the recurrence risk is slightly increased when there is a history of a previous trisomy pregnancy, but the magnitude of the increase is small.
UPD (uniparental disomy) analysis: In the mosaic form arising by trisomy rescue, the normal karyotype cells may have two copies of chromosome 18 from the same parent (UPD 18). In UPD 18, if there are imprinted genes on chromosome 18, additional clinical abnormalities may arise. To date, no clinically important imprinted genes on chromosome 18 have been established, but to reduce uncertainty, UPD analysis may be performed when clinically suspected.
Clinical phenotype according to the mosaic proportion: When the proportion of abnormal cells is below 10%, a mild or atypical phenotype is possible, and when it is 50% or more, a severe phenotype close to the complete form may appear. However, the correlation between proportion and phenotype is imperfect, and there are limits to predicting an individual's clinical course from the proportion alone.
The trisomy 18 mosaic form (Q91.1) accounts for about 2–5% of all Edwards syndrome. Because the complete form (Q91.0) accounts for the large majority at about 95%, the mosaic form is a relatively rare subtype. The translocation form (Q91.2), at about 1–2%, is even rarer than the mosaic form.
The absolute incidence of the mosaic form is estimated at about 1/100,000–1/200,000 live births, but because diagnosis may be delayed or missed owing to phenotypic heterogeneity, the actual frequency may be somewhat higher. In particular, in mild mosaic forms with a low proportion of abnormal cells, Edwards syndrome is not clinically suspected, and the diagnosis may never be made.
Sex distribution and maternal age: Unlike the complete form, the occurrence of the mosaic form has a low correlation with maternal age. This is because it arises from mitotic errors in embryonic development and can therefore occur regardless of the mother's age. The sex distribution shows a female predominance similar to the complete form, but whether there is a statistically significant difference varies by data source.
Because the survival rate of the mosaic form is higher than that of the complete form, it is more often encountered in pediatrics, developmental medicine, and adult genetics clinics. In particular, mild mosaic forms present in adulthood with nonspecific symptoms such as developmental delay, intellectual disability, and congenital heart defects, and are sometimes found incidentally during genetic testing. Since the mosaic form, unlike the complete form, may thus be encountered in adult medical practice, it is important to always consider the possibility of Edwards syndrome with an atypical phenotype.
In Korea, nationwide incidence statistics for mosaic Edwards syndrome are not yet fully systematized, but a small number of cases are identified through rare disease Special Copayment Reduction registration data. Case registration through a multidisciplinary rare disease network and long-term follow-up studies are needed.
The core pathophysiology of the trisomy 18 mosaic form is mitotic nondisjunction occurring in early embryonic development after fertilization. In normal mitosis, the two sister chromatids are distributed equally to each daughter cell by the spindle fibers. If an error in the separation of the sister chromatids of chromosome 18 occurs in this process, one daughter cell has 3 chromosomes 18 (+18 trisomic cell) and the other daughter cell has 1 chromosome 18 (−18 monosomic cell).
Selection pressure after nondisjunction determines the final distribution of the mosaic proportion. Trisomic cells (+18) can survive but may have reduced cell proliferation, and monosomic cells (−18) are disadvantaged for cell survival and are mostly eliminated during embryonic development. As a result, the embryo mostly proceeds as a mixture of normal cells and trisomic cells, and as development proceeds and cell division continues, the cell population differentiates to form tissue-specific mosaicism.
The concept that the tissues and organs in which abnormal cells are distributed determine the phenotype in the mosaic form is very important. When abnormal cells are concentrated in the cell lineage involved in cardiac development, cardiac malformations are prominent, and when abnormal cells are concentrated in the brain-forming cell lineage, nervous system malformations become the main phenotype. This tissue-specific distribution is the fundamental cause of the highly heterogeneous phenotype of the mosaic form.
Trisomy rescue mechanism: Some mosaic forms arise by a mechanism in which, from a complete trisomic zygote (a zygote in which all cells are 47,+18), the extra chromosome 18 is lost in some cells early in embryonic development, generating normal karyotype cells. Depending on which of the copies remains, maternal or paternal UPD 18 can be generated. To date, UPD 18 is known not to cause a clinically clear phenotype, but this is still under study.
At the cellular level, errors in the spindle assembly checkpoint (SAC) are proposed as the core mechanism of mitotic nondisjunction. The SAC is a surveillance mechanism that suppresses progression of mitosis until all kinetochores are correctly attached to spindle microtubules. Temporary weakening of SAC function or premature separation of cohesin is known to induce nondisjunction.
The clinical symptoms of the trisomy 18 mosaic form (Q91.1) are similar to the features of the complete form (Q91.0), but they show a very wide spectrum from mild to severe, approaching the complete form, depending on the proportion of abnormal cells and tissue distribution. This is the most important clinical feature of the mosaic form.
Cardiovascular system: As in the complete form, congenital heart defects are the most common malformation, but in the mosaic form the frequency and severity of cardiac malformations may be relatively lower. Ventricular septal defect (VSD), patent ductus arteriosus (PDA), atrial septal defect (ASD), etc. are observed. Because cardiac malformations are milder, survival is higher than in the complete form.
Nervous system and development: Intellectual disability and developmental delay are present in almost all mosaic forms, but the degree is often milder than in the complete form. In some mild mosaic forms, only mild intellectual disability or a learning disability level is reported. Motor developmental delay and language developmental delay are common. Structural brain malformations are less frequent than in the complete form.
Skeletal and musculoskeletal system: The characteristic hand posture (overlapping fingers), brachydactyly, and flexion contractures appear but are often milder than in the complete form. Rocker-bottom feet or clubfoot are also observed. Growth retardation is present in almost all affected children.
Gastrointestinal and genitourinary systems: Esophageal atresia, intestinal malformations, renal malformations, etc. may occur at a lower frequency than in the complete form. Dysphagia may be mild.
Atypical phenotype of mild mosaic form: Patients with a mild mosaic form with a low proportion of abnormal cells may show only developmental delay, growth failure, subtle facial malformations, or mild cardiac malformations that appear unrelated to Edwards syndrome. In such cases, Edwards syndrome is not clinically suspected and diagnosis may be delayed. Therefore, chromosome analysis should be considered for developmental delay of unknown cause + subtle clinical findings suggestive of Edwards syndrome.
The physical signs of the mosaic form overlap with those of the complete form, but because of phenotypic heterogeneity, the frequency and severity of particular signs vary. The main signs are described below.
Craniofacial: Microcephaly, prominent occiput, and a small face may be present, but may not be evident in mild mosaic forms. Small low-set ears, a narrow ear canal, and a short sternum may be mild or absent.
Limbs: The characteristic overlapping finger posture may be less evident than in the complete form or absent. Rocker-bottom feet or clubfoot may occur. Limb shortening is mild. Joint contractures may appear locally.
Cardiac signs: If a heart murmur is heard on auscultation, an invasive cardiac malformation is possible. Cyanosis, tachypnea, and heart failure symptoms tend to be less severe than in the complete form.
Physique and skin: Low birth weight is common but is often less severe than in the complete form. Decreased skin tension or reduced subcutaneous fat may be mild.
Neurological signs: Hypotonia or hypertonia may occur. In mild mosaic forms, neurological findings in the neonatal period may be minimal, making it difficult to distinguish from the complete form.
Prenatal ultrasound findings: The ultrasound findings seen in the complete form may appear only partially or be very subtle and thus be missed in prenatal screening tests. In confined placental mosaicism with a low proportion of abnormal cells, the prenatal cfDNA (NIPT) result may also be a false positive, so caution is needed in clinical interpretation.
The most important feature in prenatal screening for the trisomy 18 mosaic form is that screening sensitivity may be lower than for the complete form. In particular, when the proportion of abnormal cells is low, cfDNA (NIPT), serum markers, and ultrasound findings may all fall within the normal range.
Maternal serum screening (MSS): The abnormal pattern of AFP, uE3, hCG, and inhibin A may be less prominent than in the complete form. If the proportion of abnormal cells in the placenta is low, serum marker abnormalities may not be observed. Therefore, a negative serum screen does not exclude the mosaic form.
NIPT (cfDNA): Detection is possible only if the proportion of trisomic cells in the placenta is reflected in the fetal fraction. In confined placental mosaicism (CPM), even if NIPT detects fetal trisomy, the actual fetal karyotype may be normal. Conversely, in true fetal mosaicism, NIPT may be negative because the proportion of abnormal cells in the placenta is low. If there is clinical suspicion regardless of the NIPT result, invasive testing should be performed.
Prenatal ultrasound: Structural malformations may be mild or absent, so it is difficult to detect the mosaic form by ultrasound alone. When structural abnormalities (cardiac malformations, growth retardation, characteristic limb findings, etc.) are found, invasive testing including karyotype analysis or CMA is performed.
Postnatal screening: For developmental delay of unknown cause, intellectual disability, or clinical findings suggestive of Edwards syndrome in the neonatal period or childhood, standard karyotype analysis (counting at least 20–30 cells) is performed. Even if the karyotype is normal, when clinical suspicion is strong, karyotype analysis via skin fibroblast culture, SNP array, or FISH is additionally performed.
The diagnosis of the trisomy 18 mosaic form uses the same cytogenetic methods as the diagnosis of the complete form, but there are technical challenges specific to mosaicism.
Standard karyotype analysis (G-banding): The standard is to analyze at least 20–30 cells from peripheral blood lymphocytes. If the proportion of abnormal cells is 10% or more, it is mostly detected, but if it is below 5%, it may be missed by routine analysis. When the mosaic form is suspected, high-resolution analysis increasing the number of cells analyzed to 50–100 is recommended. The karyotype report must state the total number of cells analyzed and the number in each cell line.
FISH: Using a chromosome 18-specific probe, a large number of interphase cells can be analyzed rapidly. It has the advantage of analyzing more cells than karyotype analysis, so even a low proportion of abnormal cells can be detected.
Chromosomal microarray (CMA): SNP array allows quantitative detection of the mosaic form and estimation of the proportion of abnormal cells. The proportion of abnormal cells must be about 20–30% or more to be detectable on the array. In the mosaic form, array analysis cannot completely replace standard karyotype analysis.
Multi-tissue analysis: Even when peripheral blood shows a normal karyotype, if clinical suspicion is strong, additional karyotype analysis or FISH is performed on skin fibroblast culture, buccal mucosa cells, and urine cells. Because the mosaic proportion may differ by tissue, a negative result in a single tissue cannot completely exclude the mosaic form.
UPD analysis: When the mosaic form arising by trisomy rescue is suspected, the presence of UPD 18 in normal karyotype cells is checked by microarray or molecular genetic methods. The clinical significance of UPD 18 has not yet been established, but testing may be considered for the purpose of providing complete diagnostic information.
As with the complete form, treatment of the trisomy 18 mosaic form cannot correct the underlying chromosomal abnormality, so it is based on multidisciplinary supportive care and an individualized treatment plan. However, because the mosaic form has a higher survival rate and a more varied clinical course than the complete form, aggressive treatment for long-term survival carries greater weight.
Cardiac surgery: Because survival in the mosaic form is higher than in the complete form, the indications for cardiac surgery can be considered more actively. Recent studies and clinical experience report that long-term survival is possible after cardiac surgery in children with mosaic Edwards syndrome. The decision on cardiac surgery is made by the neonatology, cardiology, cardiac surgery, genetics, and palliative care teams together, reflecting the individual child's condition and the family's opinion.
Nutritional and growth support: Tube feeding (NGT or gastrostomy) is often needed. Systematic monitoring of and nutritional support for growth retardation are provided. In mild mosaic forms, oral feeding may be possible.
Developmental support and rehabilitation: Developmental intervention through physical therapy, occupational therapy, and speech therapy is started early. Linkage with special education and use of community support services are important. Because mild mosaic forms have developmental potential, aggressive early intervention is recommended.
Neurological management: Anticonvulsants are used when seizures occur. Monitoring of nervous system malformations by brain MRI and developmental neuroscience assessment are performed regularly. When hydrocephalus or brain malformations accompany, neurosurgical consultation is needed.
Family support and psychosocial support: Because the likelihood of long-term survival is higher than in the complete form, psychological support for the family, linkage to social services, and long-term care planning are important. Linkage with the palliative care team should also be made concurrently.
The prognosis of the trisomy 18 mosaic form (Q91.1) is generally better than that of the complete form, but there are large individual differences depending on the proportion of abnormal cells and the clinical phenotype.
Survival rate: The 1-year survival rate of the mosaic form is significantly higher than the 5–10% of the complete form, and some reports present 1-year survival rates of 30–40% or more. Cases surviving 3 years or 5 years or more are also much more common than in the complete form, and rare cases surviving to adulthood have been reported.
Clinical course: Long-term survival is possible when the proportion of abnormal cells is low (especially below 20%) and there is no severe cardiac malformation and no serious brain malformation. Even in such cases, intellectual disability, developmental delay, and growth failure remain persistent problems in most. There are also case reports that in mild mosaic forms, nonverbal communication develops and a life at the level of responding to simple environmental stimuli is possible.
Limits of prognostic prediction: Because the correlation between the proportion of abnormal cells and phenotype is incomplete, it is impossible to accurately predict long-term prognosis from the proportion in peripheral blood alone. The distribution of cells in key organs is decisive, but this is difficult to measure directly in clinical practice.
Comparison with the complete form: The mosaic form shows significantly better survival than the complete form (Q91.0), in which all cells are abnormal. This difference is attributed to reduced severity of cardiac malformations, reduced frequency of brain malformations, and overall improvement in multi-organ function. However, normal development cannot be expected in any mosaic form.
Because the trisomy 18 mosaic form arises from random errors in embryonic development after fertilization, there is no currently known method of prevention. Unlike the complete form, the advanced maternal age risk factor is weak, so it can occur in young mothers as well. Approaches related to prevention are as follows.
Prenatal screening and diagnosis: The mosaic form may be missed by NIPT or serum screening, but the screening tests currently available in clinical practice are used to the fullest. When structural abnormalities are found on ultrasound, invasive testing including karyotype analysis is performed. A positive NIPT result must be confirmed by invasive testing, and the complete form must also be distinguished from the mosaic form.
Genetic counseling: To parents who have delivered a child with the mosaic form, it is explained that the recurrence risk is low, as with the complete form, and prenatal genetic diagnosis options for the next pregnancy are presented. Because the phenotype of the mosaic form is variable by nature, it is important to explain thoroughly that, even if the proportion of abnormal cells is determined at prenatal diagnosis, the fetus's clinical prognosis cannot be predicted accurately.
PGT-A: Detecting mosaic embryos in embryo screening through assisted reproduction (PGT-A) is technically possible, but there is still uncertainty in interpreting the clinical significance of mosaic embryos with a low proportion. When a mosaic embryo is found on PGT-A, the decision on whether to transfer must be made through expert counseling and ethical review.
Establishing a long-term follow-up system: Because data on the long-term prognosis of children with the mosaic form are lacking, case registration through domestic and international rare disease registries and long-term follow-up studies are needed to improve prevention and treatment strategies.